Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients

Autor:	Minh Patrick Lê, Vincent Calvez, Cathia Soulié, Yazdan Yazdanpanah, Philippe Choisy, Enagnon Kazali Alidjinou, Diane Descamps, A G Marcelin, Charlotte Charpentier, Christine Katlama, Faiza Ajana, Laurence Bocket, Anne Simon, Gilles Peytavin
Rok vydání:	2016
Předmět:	0301 basic medicine Microbiology (medical) Adult Male medicine.medical_specialty 030106 microbiology Human immunodeficiency virus (HIV) HIV Infections medicine.disease_cause Gastroenterology Virological response Maraviroc 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Cyclohexanes Internal medicine Antiretroviral Therapy Highly Active medicine Humans Pharmacology (medical) 030212 general & internal medicine Aged Pharmacology Univariate analysis business.industry Middle Aged Triazoles Viral Load Raltegravir Hiv subtype Virology Regimen Infectious Diseases Treatment Outcome chemistry Anti-Retroviral Agents CCR5 Receptor Antagonists HIV-1 Female business Viral load medicine.drug
Zdroj:	The Journal of antimicrobial chemotherapy. 71(9)
ISSN:	1460-2091
Popis:	OBJECTIVES There are few data on clinical and virological factors associated with maraviroc virological response (VR) in clinical practice. This study aimed to identify factors associated with VR in 94 treatment-experienced, but CCR5 inhibitor-naive, HIV-1 patients switched to maraviroc-containing regimens. METHODS Patients with HIV-1 RNA viral load (VL)
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::345e2c6f7e3150d834ead882a473387a https://pubmed.ncbi.nlm.nih.gov/27234463 Zobrazit plný text záznamu